References
A. Mathur, N. Nagarajan, S. Kahan, E.B. Schneider, M.A. Zeiger, Association of parathyroid hormone level with postthyroidectomy hypocalcemia: a systematic review. JAMA Surg. 153(1), 69–76 (2018). https://doi.org/10.1001/jamasurg.2017.3398
F. Tecilazich, A.M. Formenti, S. Frara, R. Giubbini, A. Giustina, Treatment of hypoparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. (2018). https://doi.org/10.1016/j.beem.2018.12.002
M. Mannstadt, B.L. Clarke, T. Vokes, M.L. Brandi, L. Ranganath, W.D. Fraser et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 1(4), 275–283 (2013). https://doi.org/10.1016/S2213-8587(13)70106-2
J. Bollerslev, L. Rejnmark, C. Marcocci, D.M. Shoback, A. Sitges-Serra, W. van Biesen et al. European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults. Eur. J. Endocrinol. 173(2), G1–G20 (2015). https://doi.org/10.1530/EJE-15-0628
S.J. Rosenstreich, C. Rich, W. Volwiler, Deposition in and release of vitamin D3 from body fat: evidence for a storage site in the rat. J. Clin. Investig. 50(3), 679–687 (1971). https://doi.org/10.1172/JCI106538
A. Pramono, J.W.E. Jocken, Y.P.G. Essers, G.H. Goossens, E.E. Blaak, Vitamin D and tissue-specific insulin sensitivity in humans with overweight/obesity. J. Clin. Endocrinol. Metab. 104(1), 49–56 (2019). https://doi.org/10.1210/jc.2018-00995
M. Garabedian, Y. Tanaka, M.F. Holick, H.F. Deluca, Response of intestinal calcium transport and bone calcium mobilization to 1,25-dihydroxyvitamin D3 in thyroparathyroidectomized rats. Endocrinology 94(4), 1022–1027 (1974). https://doi.org/10.1210/endo-94-4-1022
Funding
This study was funded by the European Commission (grant number 795877 to F.T.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
A.G. has received research grants from Ipsen and Novartis and is a consultant for Ipsen, Pfizer, Astellas, and Shire. A.M.F. is consultant for Shire. F.T. declares that he has no conflict of interest. The remaining authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Written informed consent was waived.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Formenti, A.M., Tecilazich, F., Frara, S. et al. Body mass index predicts resistance to active vitamin D in patients with hypoparathyroidism. Endocrine 66, 699–700 (2019). https://doi.org/10.1007/s12020-019-02105-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-019-02105-6